913 related articles for article (PubMed ID: 30131656)
1. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
2. Liver Inflammation and Hepatobiliary Cancers.
Leone V; Ali A; Weber A; Tschaharganeh DF; Heikenwalder M
Trends Cancer; 2021 Jul; 7(7):606-623. PubMed ID: 33674229
[TBL] [Abstract][Full Text] [Related]
3. Lymphoepithelioma-Like Carcinoma in Liver.
Labgaa I; Stueck A; Ward SC
Am J Pathol; 2017 Jul; 187(7):1438-1444. PubMed ID: 28500863
[TBL] [Abstract][Full Text] [Related]
4. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?
Parks AL; McWhirter RM; Evason K; Kelley RK
J Gastrointest Cancer; 2015 Jun; 46(2):161-5. PubMed ID: 25662892
[No Abstract] [Full Text] [Related]
5. Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma.
Coulouarn C; Clément B
J Hepatol; 2014 Jun; 60(6):1306-9. PubMed ID: 24530649
[TBL] [Abstract][Full Text] [Related]
6. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
Ma L; Hernandez MO; Zhao Y; Mehta M; Tran B; Kelly M; Rae Z; Hernandez JM; Davis JL; Martin SP; Kleiner DE; Hewitt SM; Ylaya K; Wood BJ; Greten TF; Wang XW
Cancer Cell; 2019 Oct; 36(4):418-430.e6. PubMed ID: 31588021
[TBL] [Abstract][Full Text] [Related]
7. L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma.
Min JK; Kim JM; Li S; Lee JW; Yoon H; Ryu CJ; Jeon SH; Lee JH; Kim JY; Yoon HK; Lee YK; Kim BH; Son YS; Choi HS; Lim NK; Kim DG; Hong HJ
Clin Cancer Res; 2010 Jul; 16(14):3571-80. PubMed ID: 20501614
[TBL] [Abstract][Full Text] [Related]
8. Characterization of CD133+ parenchymal cells in the liver: histology and culture.
Yoshikawa S; Zen Y; Fujii T; Sato Y; Ohta T; Aoyagi Y; Nakanuma Y
World J Gastroenterol; 2009 Oct; 15(39):4896-906. PubMed ID: 19842219
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of Hepatocellular Carcinoma.
Heinrich B; Czauderna C; Marquardt JU
Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
[TBL] [Abstract][Full Text] [Related]
10. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas.
Okamura N; Yoshida M; Shibuya A; Sugiura H; Okayasu I; Ohbu M
Pathol Int; 2005 Nov; 55(11):724-31. PubMed ID: 16271085
[TBL] [Abstract][Full Text] [Related]
11. Hepatobiliary cancers, version 2.2014.
Benson AB; D'Angelica MI; Abrams TA; Are C; Bloomston PM; Chang DT; Clary BM; Covey AM; Ensminger WD; Iyer R; Kelley RK; Linehan D; Malafa MP; Meranze SG; Park JO; Pawlik T; Posey JA; Scaife C; Schefter T; Sigurdson ER; Tian GG; Vauthey JN; Venook AP; Yen Y; Zhu AX; Hoffmann KG; McMillian NR; Sundar H
J Natl Compr Canc Netw; 2014 Aug; 12(8):1152-82. PubMed ID: 25099447
[TBL] [Abstract][Full Text] [Related]
12. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Gbolahan O; Hashemi-Sadraei N; O'Neil B
J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359
[TBL] [Abstract][Full Text] [Related]
13. Combined hepatocellular carcinoma and cholangiocarcinoma: a case report and review of the literature.
Zhou YM; Yang JM; Wang B; Xu F; Tong Y; Li DQ
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):656-9. PubMed ID: 18086637
[TBL] [Abstract][Full Text] [Related]
14. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
Xia Y; Brown ZJ; Huang H; Tsung A
Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
[TBL] [Abstract][Full Text] [Related]
15. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
Zhou G; Boor PPC; Bruno MJ; Sprengers D; Kwekkeboom J
Br J Cancer; 2022 Jan; 126(1):10-23. PubMed ID: 34400801
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment: Necroptosis Switches the Subtype of Liver Cancer While Necrosis Promotes Tumor Recurrence and Progression.
Özdemir BH
Exp Clin Transplant; 2023 Apr; 21(4):291-298. PubMed ID: 35297332
[TBL] [Abstract][Full Text] [Related]
17. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
18. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
19. Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma.
Shetty AS; Fowler KJ; Brunt EM; Agarwal S; Narra VR; Menias CO
Abdom Imaging; 2014 Apr; 39(2):310-22. PubMed ID: 24407728
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
